respiratori
virus
caus
infect
upper
lower
respiratori
tract
viral
infect
lower
respiratori
tract
caus
sever
respiratori
syndrom
bronchiti
pneumonia
bronchiol
particular
children
elderli
greatli
affect
sever
import
virus
infect
epitheli
cell
human
respiratori
tract
respiratori
syncyti
viru
rsv
influenza
b
virus
parainfluenza
adenoviru
virus
infect
human
respiratori
tract
includ
rhinoviru
human
metapneumoviru
hmpv
sever
acut
respiratori
syndrom
coronaviru
human
coronaviru
parainfluenza
bocaviru
among
respiratori
virus
influenza
lead
caus
respiratori
ill
global
human
popul
affect
influenza
viru
annual
accord
report
world
health
organ
everi
year
death
occur
due
infect
influenza
viru
differ
platform
influenza
vaccin
avail
market
inactiv
split
vaccin
live
attenu
influenza
vaccin
laiv
recombin
purifi
subunit
protein
vaccin
human
respiratori
syncyti
viru
rsv
caus
respiratori
tract
infect
infant
young
children
worldwid
lead
acut
bronchiol
viral
pneumonia
extens
epidem
studi
indic
approxim
hospit
admiss
inhospit
death
due
rsvinduc
acut
lower
respiratori
infect
children
younger
month
thirtythre
million
case
worldwid
children
age
estim
infect
rsvassoci
acut
lower
respiratori
infect
patient
hospit
result
inhospit
death
palivizumab
licens
monoclon
antibodi
ab
use
prophylact
drug
prevent
sever
rsv
diseas
highrisk
children
sinc
palivizumab
safeti
efficaci
concern
anaphylaxi
hypersensit
reaction
palivizumab
recommend
therapeutictreat
postrsv
infect
neither
effect
therapi
licens
vaccin
commerci
avail
market
rsv
far
anoth
import
respiratori
viru
human
metapneumoviru
hmpv
also
lead
caus
acut
lower
respiratori
tract
infect
global
pediatr
popul
immunocompromis
patient
greatli
suscept
hmpv
caus
substanti
morbid
mortal
worldwid
howev
current
hmpvspecif
vaccin
avail
viruslik
particl
vlp
develop
report
suggest
effect
vaccin
platform
respiratori
virus
influenza
viru
rsv
hmpv
infect
figur
vlp
nonrepl
well
noninfecti
contain
viral
genet
materi
viral
structur
protein
envelop
viral
glycoprotein
capsid
core
protein
express
selfassembl
particul
morpholog
vlp
cell
cultur
vitro
vlp
produc
bacteria
mammalian
cell
line
insect
cell
line
yeast
plant
cell
vlp
produc
recombin
baculoviru
deriv
construct
exhibit
higher
broader
immun
respons
compar
mammalian
express
vlp
vaccin
possibl
residu
baculovirus
vlp
prepar
activ
innat
immun
respons
site
inocul
vlp
provid
immunogen
platform
effect
elicit
cell
b
cell
immun
respons
due
repetit
high
densiti
viral
protein
display
surfac
vlp
review
attempt
cover
product
immunogen
properti
vaccin
efficaci
vlp
vaccin
preclin
clinic
studi
report
respiratori
virus
influenza
virus
rsv
hmpv
differ
approach
report
gener
influenza
vlp
vaccin
influenza
vlp
compos
variou
structur
influenza
protein
hemagglutinin
ha
neuraminidas
na
matrix
protein
figur
vlp
contain
four
structur
protein
deriv
influenza
viru
produc
insect
cell
via
recombin
baculoviru
rbv
express
system
three
ha
na
proteinencod
gene
clone
singl
baculoviru
construct
express
gener
influenza
viru
vlp
tabl
also
individu
rbv
express
ha
coinfect
togeth
insect
cell
produc
influenza
vlp
sever
advantag
use
baculoviru
express
vector
system
bev
protein
express
bev
solubl
function
activ
advantag
bev
includ
posttransl
modif
higher
yield
secret
protein
mammalian
cellexpress
vlp
report
produc
human
embryon
kidney
cell
transfect
dna
plasmid
express
influenza
surfac
protein
core
matrix
protein
tabl
brief
mammalian
cell
cotransfect
three
differ
clone
recombin
plasmid
ha
na
respect
apuerto
strain
na
codonoptim
ha
protein
clade
plant
cell
use
express
product
recombin
ha
influenza
vlp
vaccin
current
clinic
trial
evalu
immunogen
safeti
efficaci
tabl
variou
form
recombin
ha
includ
monom
trimer
viruslik
particl
chimer
protein
obtain
plantbas
technolog
nicotiana
benthamiana
plant
vacuum
infiltr
batch
agrobacterium
inoculum
contain
ha
express
cassett
vlp
obtain
harvest
plant
cell
homogen
purif
plantmad
vlp
show
morpholog
stabl
structur
time
elicit
humor
cellular
respons
mice
ferret
rabbit
chicken
tabl
plantderiv
vaccin
report
induc
significantli
higher
level
igg
antibodi
cell
respons
compar
inactiv
viru
vaccin
age
mice
taken
togeth
influenza
vlp
compos
ha
na
either
contain
three
protein
two
protein
ha
na
vlp
vaccin
contain
structur
protein
season
influenza
viru
subtyp
immunogen
induc
humor
antibodi
cellular
immun
respons
studi
report
influenza
vlp
could
provid
protect
homolog
heterolog
protect
differ
degre
efficaci
depend
antigen
close
tabl
rbv
express
system
produc
season
trival
vlp
vaccin
deriv
influenza
viru
anew
anew
influenza
b
viru
abl
elicit
substanti
level
hemagglutin
inhibit
hai
titer
homolog
heterolog
viru
challeng
mous
ferret
model
tabl
studi
mice
immun
vlp
ferret
immun
trival
vlp
vaccin
found
elicit
higher
level
influenzaspecif
cell
respons
mice
commerci
eggderiv
trivalentinactiv
vaccin
tiv
influenza
vlp
vaccin
provid
higher
vaccin
efficaci
homolog
heterolog
viru
challeng
infect
compar
heterosubtyp
influenza
viru
show
less
bodi
weight
loss
anim
model
challeng
homolog
heterolog
viru
result
indic
efficaci
influenza
vlp
vaccin
encourag
preclin
studi
altern
vaccin
platform
howev
protect
efficaci
vari
divers
vlp
vaccin
contain
differ
antigen
compon
content
efficaci
studi
report
inbr
mous
model
might
predict
happen
human
vaccin
influenza
vlp
vaccin
need
better
character
test
outbr
relev
anim
model
develop
improv
crossprotect
immun
consider
futur
vaccin
influenza
pandem
outbreak
novel
influenza
viru
spread
worldwid
influenza
pandem
observ
signific
shortag
delay
eggbas
vaccin
global
suppli
technolog
nonrepl
vlp
repres
altern
option
sinc
immunogen
safe
independ
egg
suppli
previou
studi
report
influenza
vlp
contain
ha
na
surfac
protein
highli
pathogen
avian
influenza
virus
induc
high
titer
neutral
antibodi
mice
influenza
vlp
vlp
gener
use
rbv
express
systeminduc
encourag
protect
immun
mice
ferret
tabl
ha
vlp
assembl
ha
wildtyp
hawt
ha
transmembran
tm
domain
replac
subtyp
hatm
gener
vlpstm
induc
better
protect
homolog
heterolog
virus
challeng
observ
less
weight
loss
higher
surviv
rate
compar
vlpswt
bival
heterolog
dna
vlp
primeboost
vaccin
report
provid
protect
virus
mice
prime
dna
plasmid
twice
week
boost
vlp
immun
sera
vaccin
mice
abl
neutral
homolog
heterolog
heterosubtyp
viru
passiv
transfer
irina
tretyakova
colleagu
report
quadrival
pseudotyp
influenza
vlp
vaccin
contain
four
differ
type
ha
protein
na
bovin
immunodefici
viru
gag
protein
b
gag
altern
matrix
protein
insect
cell
tabl
electron
microscop
observ
result
demonstr
averag
size
b
gag
core
protein
assembl
vlp
rang
nm
nm
larger
influenza
viru
core
protein
assembl
vlp
result
indic
vaccin
efficaci
avian
influenza
vlp
encourag
b
gag
core
protein
assembl
vlp
might
incorpor
spike
antigen
assembl
vlp
influenza
viru
surfac
antigen
protein
ha
na
chang
time
result
gener
novel
virus
antigen
differ
becom
new
ha
andor
new
ha
na
protein
influenza
virus
new
research
effort
develop
univers
influenza
vlp
contain
ha
na
protein
go
broader
extracellular
domain
conserv
among
influenza
virus
use
crossprotect
antigen
target
crossprotect
efficaci
observ
vaccin
mice
vlp
vaccin
contain
heterolog
tandem
repeat
deriv
human
swine
avian
influenza
virus
heterolog
tandem
repeat
construct
contain
multipl
conserv
epitop
increas
densiti
epitop
compar
studi
vaccin
efficaci
conduct
mice
vlp
wildtyp
express
vlp
studi
demonstr
vlp
immun
induc
protect
howev
wildtyp
vlpvaccin
mice
show
signific
loss
bodi
weight
substanti
delay
recov
bodi
weight
tabl
vlp
vaccin
could
induc
longlast
crossprotect
reassort
viru
passiv
transfer
immun
sera
vaccin
mice
mice
anoth
experiment
data
demonstr
vlp
vaccin
abil
show
crossprotect
efficaci
balbc
mice
compar
mice
suggest
immunogen
efficaci
depend
host
strain
efficaci
crossprotect
vlp
immun
mediat
weak
nonneutr
immun
respons
supplement
habas
influenza
vaccin
vlp
vaccin
could
significantli
enhanc
crossprotect
mice
chicken
ferret
result
indic
higher
vaccin
efficaci
crossprotect
induc
vlp
induc
supplement
influenza
vaccin
differ
adjuv
test
influenza
vaccin
epitop
includ
freund
adjuv
monophosphoryl
lipid
cholera
toxin
subunit
heatlabil
endotoxin
flagellin
profilin
provid
certain
level
broader
enhanc
crossprotect
iscomatrix
compos
purifi
fraction
quillaia
saponaria
extract
cholesterol
phospholipid
test
influenza
vlp
vaccin
base
vlp
vaccin
iscomatrix
adjuv
shown
induc
higher
level
serum
hai
na
antibodi
titer
provid
better
protect
mice
heterosubtyp
viru
heterolog
viru
compar
vlp
vaccin
influenza
vlp
engin
express
molecular
adjuv
immunostimulatori
molecul
surfac
vlp
flagellin
molecular
adjuv
engin
incorpor
influenza
vlp
vaccin
via
membraneanchor
domain
figur
flagellincontain
influenza
vlp
produc
insect
cell
coinfect
rbv
express
ha
membraneanchor
flagellin
chimer
flagellin
plu
ha
vlp
vaccinationinduc
heterosubtyp
protect
challeng
aphilippin
viru
also
flagellin
vlp
found
play
effect
adjuv
role
promot
igg
isotypeswitch
longlast
antibodi
induct
protect
influenza
vaccin
condit
mice
use
protein
transfer
technolog
glycosylphosphatidylinositol
anchor
immunostimulatori
molecul
gpiism
incorpor
onto
influenza
vlp
mice
immun
vlp
modifi
protein
transfer
gpigmcsf
induc
higher
level
igg
antibodi
respons
protect
heterolog
influenza
viru
challeng
unmodifi
vlp
mice
intranas
immun
chimer
vlp
contain
influenza
ha
antigen
shown
induc
longlast
mucos
immun
viru
infect
gpianchor
chemokin
coexpress
surfac
influenza
ha
vlp
shown
effect
reduc
lung
viral
titer
viru
challeng
vaccin
mice
vaccin
mice
influenza
ha
vlp
contain
gpianchor
enhanc
lung
iga
serum
igg
antibodi
respons
compar
standard
influenza
ha
vlp
vaccin
yeast
express
system
rather
use
bacteri
express
system
use
avoid
bacteri
endotoxin
studi
long
alpha
helix
domain
amino
acid
residu
conserv
ha
stalk
region
genet
fuse
hepat
b
viru
hbv
core
protein
express
via
yeast
express
system
hydrophob
stalk
domain
fragment
present
immunogen
spike
surfac
selfassembl
hbv
core
protein
vlp
chimer
ha
stalk
hbv
core
vlp
produc
yeast
cell
immunogen
induc
igg
antibodi
respons
group
group
ha
protein
mice
vaccin
combin
adjuv
cpg
odn
sequenceoptim
rna
rigi
agonist
use
adjuv
enhanc
influenza
vlp
efficaci
immun
novel
adjuv
vlp
contain
influenza
viru
ha
na
induc
humor
cellular
mediat
protect
respons
protect
influenza
viru
challeng
intramuscular
immun
induc
longlast
protect
antibodi
respons
influenza
viru
mice
intramuscular
immun
freund
adjuv
influenza
vlp
contain
ha
na
induc
high
level
hai
titer
signific
reduct
viru
shed
substanti
homolog
protect
chicken
adjuv
alum
cpg
dna
monophosphoryl
lipid
mpl
poli
ic
gardiquimod
cholera
toxin
ct
use
assess
immun
combin
influenza
vlp
mice
alum
cpg
mpl
ct
adjuv
vlp
show
higher
level
antibodi
sera
mucosa
alum
mpl
ct
adjuv
vlp
show
higher
hai
virusneutr
activ
compar
non
adjuv
control
studi
support
concept
chimer
vlp
adjuv
influenza
vlp
vaccin
effect
induc
antibodi
respons
protect
standard
vlp
control
howev
chimer
vlp
adjuv
influenza
vlp
vaccin
test
mous
model
remain
unclear
efficaci
safeti
translat
applic
human
human
respiratori
syncyti
viru
rsv
belong
pneumovirida
famili
contain
fusion
protein
f
attach
g
glycoprotein
surfac
virion
direct
toward
outsid
virion
membran
f
glycoprotein
rel
conserv
among
differ
rsv
b
strain
rsv
f
g
glycoprotein
contain
b
cell
cell
epitop
gener
protectiveimmun
respons
host
natur
infect
although
rsv
contain
anoth
surfac
glycoprotein
sh
glycoprotein
natur
weakli
immunogen
rsv
vlp
vaccin
gener
express
rsv
g
f
glycoprotein
seen
figur
b
tabl
newcastl
diseas
viru
ndv
vlp
contain
ectodomain
rsv
g
f
protein
gener
recombin
chimer
rsvndv
construct
rsv
g
f
protein
fuse
cytoplasm
tail
ct
transmembran
tm
domain
ndv
hemagglutininneuraminidas
hn
f
protein
gener
produc
rsv
vlp
vaccin
base
ndv
structur
protein
interact
tmct
chimer
rsvndv
glycoprotein
ndv
nucleoprotein
np
matrix
protein
necessari
effici
product
chimer
rsvndv
vlp
vaccin
avian
cell
dna
transfect
chimer
f
ff
g
hg
protein
togeth
copres
surfac
ndvvlp
help
ndv
structur
protein
vlp
assembl
bud
chimer
rsv
ndv
vlp
vaccin
contain
rsv
g
rsv
g
f
protein
immunogen
prevent
replic
rsv
mice
without
caus
vaccineenhanc
rsv
lung
histopatholog
rsv
f
protein
two
form
conform
one
metast
prefus
f
protein
conform
anoth
stabl
postfus
f
protein
form
prefus
form
rsvf
protein
contain
potent
neutral
epitop
site
v
expos
postfus
form
prefus
f
conformationstabil
protein
report
introduc
prefus
stabil
mutat
cystin
disulfid
bond
format
point
mutat
caviti
fill
well
foldon
oligom
stabil
domain
present
prefus
f
protein
surfac
vlp
prefus
stabil
prefus
f
without
foldon
domain
fuse
tm
ndv
f
protein
recent
studi
report
ndv
vlp
contain
prefus
f
stabil
singl
chain
f
delet
peptid
sequenc
cleavag
site
point
mutat
could
induc
higher
rsv
neutral
antibodi
cotton
rat
compar
ndv
vlp
f
rsv
vlp
also
gener
use
influenza
matrix
protein
core
protein
rsv
g
f
fulllength
glycoprotein
express
insect
cell
via
rbv
contain
gene
encod
g
f
protein
rsvf
rsvg
vlp
observ
spheric
shape
spike
surfac
morpholog
rsv
f
vlp
display
rang
size
distribut
approxim
nm
diamet
wherea
gvlp
similar
somewhat
heterogen
size
rsv
vlp
also
report
gener
transfect
mammalian
cell
three
type
express
plasmid
contain
codon
optim
rsvg
f
protein
rsv
vlp
appear
mimic
nativ
rsv
morpholog
structur
examin
transmiss
electron
microscopi
region
within
central
rsv
g
protein
locat
amino
acid
report
contain
protect
epitop
induc
helper
cell
th
cell
respons
eosinophilia
tandem
repeat
gene
encod
rsv
g
protein
region
contain
cell
b
cell
epitop
motif
util
gener
rsv
g
fragment
vlp
g
vlp
contain
tandem
repeat
g
fragment
protein
could
provid
protect
rsv
vaccin
mice
challeng
rsv
differ
platform
rsv
f
protein
nanoparticl
vaccin
gener
advanc
clinic
trial
near
fulllength
rsv
f
protein
transmembran
domain
contain
mutat
enhanc
express
insect
cell
surfac
use
rbv
express
system
purifi
deterg
condit
formul
nanoparticl
found
highli
immunogen
induc
neutral
antibodi
cotton
rat
follow
studi
prefusogen
f
nanoparticl
vaccin
found
induc
neutral
antibodi
competit
monoclon
antibodi
target
multipl
antigen
site
present
pref
postf
conform
taken
togeth
rsv
g
f
protein
could
present
vlp
formul
nanoparticl
util
differ
strategi
immunogen
could
induc
protect
immun
respons
anim
model
alumadjuv
formalininactiv
rsv
firsv
vaccin
fail
provid
protect
children
clinic
trial
vaccineenhanc
respiratori
diseas
upon
rsv
infect
observ
winter
epidem
season
safeti
concern
appli
inactiv
subunit
rsv
vaccin
young
children
impli
absenc
licens
rsv
vaccin
challeng
difficult
develop
effect
safe
rsv
vaccin
induc
protect
rsv
neutral
immun
avoid
rsv
vaccinationinduc
respiratori
diseas
rsv
infect
comparison
studi
rsv
f
vlp
alumadjuv
firsv
f
vlp
intranas
immun
mice
induc
helper
type
bias
antibodi
neutral
immun
rsv
dendrit
cell
fspecif
cell
display
least
weight
loss
sign
histopatholog
eosinophilia
contrast
alumadjuv
firsv
immun
mice
show
sever
lung
histopatholog
eosinophilia
togeth
high
level
tnf
cell
respons
despit
lung
viral
control
rsv
challeng
chimer
rsvndv
vlp
contain
ectodomain
rsv
f
g
g
protein
alon
confer
protect
rsv
challeng
infect
mice
without
display
enhanc
respiratori
lung
inflamm
immun
mice
rsv
vlp
vaccin
contain
either
f
g
protein
induc
rsv
specif
igg
antibodi
sera
lung
extract
rsv
vlp
vaccin
mice
induc
neutral
antibodi
correl
reduc
lung
viral
load
protect
mice
rsv
challeng
infect
rsv
vlp
compos
rsv
g
f
protein
elicit
high
titer
igg
antibodi
respons
homolog
rsv
heterolog
rsv
b
strain
challeng
mammalian
cellderiv
rsv
vlp
vaccin
adjuv
combin
alum
monophosphoryl
lipid
induc
higher
level
igg
titer
nonadjuv
vlp
rsv
vlp
vaccin
combin
postfus
prefus
f
glycoprotein
afford
higher
neutral
titer
helper
type
immun
respons
effect
prevent
lung
viral
replic
compar
either
postfus
f
prefus
f
vlp
vaccin
challeng
mice
vaccin
mice
combin
rsv
f
vlp
f
g
vlp
induc
cell
respons
provid
addit
protect
prevent
lung
immunopatholog
challeng
rsv
g
alon
vlp
vaccin
result
substanti
lung
histopatholog
rsv
challeng
vlp
vaccin
contain
tandem
repetit
rsv
g
fragment
abl
provid
recal
b
cell
respons
protect
lung
viral
replic
rsv
challeng
also
immun
combin
rsv
vlp
vaccin
f
g
f
dna
ffg
vlp
induc
isotyp
antibodi
respons
rsv
f
effect
prevent
lung
histopathogloy
rsv
challeng
immun
induc
live
rsv
prior
infect
addit
combin
ffg
vlp
vaccin
induc
higher
ratio
versu
versu
cell
addit
effect
clear
lung
viral
load
interestingli
prime
immun
mice
rsv
f
vlp
vaccin
induc
immun
respons
prevent
induct
lung
histopatholog
due
subsequ
firsv
vaccin
uniqu
immunogen
properti
rsv
f
vlp
platform
evid
studi
report
solubl
f
protein
vaccin
exacerb
pulmonari
histopatholog
upon
rsv
challeng
present
vlp
mous
model
individu
consid
infect
rsv
age
two
three
year
old
live
rsv
infect
provid
longterm
protect
immun
recent
studi
demonstr
avian
cellderiv
vlp
vaccin
contain
ectodomain
rsv
g
preff
protein
highli
effect
induc
higher
level
rsv
neutral
antibodi
even
presenc
prior
rsv
infect
mous
model
compar
rsv
reinfect
mice
cotton
rat
known
permiss
rsv
infect
thu
consid
prefer
anim
model
mice
rsv
pathogenesi
vaccin
efficaci
studi
vlp
vaccin
contain
two
chimer
rsv
ectodomain
glycoprotein
chimer
prefus
ff
hg
shown
confer
protect
rsv
replic
upon
rsv
challeng
cotton
rat
ndvrsv
vlp
contain
stabil
prefus
ff
chimera
protein
effect
induc
higher
titer
serum
neutral
activ
compar
low
dose
live
rsv
prior
infect
preff
vlp
immun
protect
cotton
rat
result
enhanc
lung
inflamm
rsv
challeng
combin
f
g
vlp
f
dna
vaccin
cotton
rat
effect
induc
rsv
neutral
antibodi
titer
rsv
f
combin
ffg
vlp
f
vlp
vaccin
prevent
induct
vaccineinduc
inflamm
lung
contrast
firsv
matern
vaccin
rsv
vlp
f
nanoparticl
vaccin
provid
insight
protect
infant
rsv
infect
rsv
f
nanoparticl
protein
chimer
ndvrsv
vlpinduc
immun
could
transfer
mother
infant
pregnant
cotton
rat
intramuscularli
immun
rsv
prefus
fg
vlp
rsv
f
nanoparticl
protein
vaccin
evalu
protect
role
matern
transfer
immun
infant
placent
barrier
offspr
pup
born
vaccin
cotton
rat
protect
rsv
infect
pulmonari
inflamm
rsv
f
nanoparticl
protein
vaccin
induc
polyclon
palivizumabcompetit
high
neutral
activ
rsv
b
virus
activ
passiv
immun
cotton
rat
result
indic
studi
rsv
vaccin
base
vlp
nanoparticl
platform
expect
provid
import
insight
develop
effect
safe
rsv
vaccin
human
metapneumoviru
hmpv
also
envelop
viru
belong
pneumovirida
famili
contain
protein
core
protein
encircl
lipid
membran
express
three
hmpv
surfac
antigen
f
g
sh
f
protein
requir
viru
assembl
fusion
entri
primari
target
neutral
antibodi
hmpvvlp
produc
coexpress
f
g
protein
along
core
matrix
protein
mammalian
cellbas
dna
transfect
studi
also
reveal
new
find
hmpv
vlp
assembl
hmpvg
protein
independ
facilit
format
vlp
addit
express
hmpvf
protein
surfac
vlp
larg
depend
associ
hmpvg
anoth
group
research
produc
hmpv
vlp
use
retrovirusderiv
gag
core
protein
murin
leukemia
viru
gag
protein
use
core
particl
gener
hmpv
vlp
contain
hmpv
g
f
glycoprotein
either
lineag
b
hmpv
vlp
also
gener
express
viral
protein
matrix
f
protein
suspensionadapt
human
embryon
kidney
epitheli
cell
mammalian
cellbas
express
system
studi
fulllength
f
viral
protein
sequenc
deriv
pathogen
clinic
hmpv
genotyp
isol
respect
recent
anoth
group
research
report
gener
hmpv
vlp
mammalian
cellbas
express
system
express
rsv
prefus
f
protein
delet
introduct
disulfid
bond
stabil
prefus
f
post
fusion
f
protein
metapneumoviru
protein
use
core
protein
codon
optim
rsv
prefus
f
postfus
f
sequenc
fuse
tm
hmpvf
protein
gener
rsvhmpv
vlp
hmpv
vlp
vaccin
display
f
g
surfac
glycoprotein
lineag
b
provid
protect
hmpv
challeng
mice
tabl
hmpv
vlp
immun
mice
show
serum
neutral
antibodi
signific
reduct
lung
viral
titer
challeng
adjuv
hmpv
vlp
express
hmpv
f
matrix
could
provid
complet
protect
hmpv
replic
lung
mice
hmpv
vlp
immun
induc
fspecif
igg
antibodi
cell
respons
recogn
f
protein
epitop
hmpv
vlp
vaccin
adjuv
either
titermax
gold
enhanc
neutralizingantibodi
respons
mice
studi
demonstr
serum
neutral
antibodi
alon
might
suffici
longlast
protect
reinfect
hmpv
cell
immun
togeth
would
import
protect
reinfect
longterm
protect
importantli
hmpv
vlp
vaccin
caus
enhanc
respiratori
diseas
upon
viral
challeng
previou
studi
indic
hmpv
vaccin
base
vlp
produc
mammalian
cell
could
effect
induc
protect
immun
hmpv
season
influenza
vlp
vaccin
might
provid
compar
effect
protect
inactiv
split
vaccin
produc
egg
substrat
phaseiii
doubleblind
dose
depend
vaccin
efficaci
studi
conduct
mexico
pandem
viru
evalu
vaccin
safeti
immunogen
influenza
havlp
produc
insect
cell
via
rbv
express
system
tabl
vlp
vaccin
safe
well
toler
healthi
adult
age
vaccin
vlp
vaccin
ha
dose
low
dose
ha
ha
vlp
vaccin
found
immunogen
safe
vaccin
local
advers
event
observ
moder
ha
high
dose
ha
group
low
dose
ha
subject
placebo
group
display
local
seriou
advers
event
vaccin
notabl
follow
clinic
studi
influenza
vlp
vaccin
subject
observ
seroprotect
antibodi
level
hai
titer
boost
anoth
phase
iii
dose
depend
clinic
trial
approv
food
drug
administr
conduct
healthi
adult
determin
efficaci
rbvinsect
cellderiv
vlp
vaccin
clinic
studi
differ
dose
ha
ha
test
found
induc
function
antibodi
preferenti
recogn
oligomer
form
hemagglutinin
low
hai
titer
observ
doseimmun
subject
wherea
high
hai
titer
crossreact
clade
virus
induc
individu
ha
vlp
dose
immun
seriou
local
system
advers
event
singl
subject
discontinu
due
advers
event
addit
clinic
studi
avian
influenza
vlp
vaccin
unadjuv
vlp
vaccin
exhibit
poor
antibodi
respons
contrast
iscomatrixtm
adjuv
vlp
vaccin
elicit
hai
respons
rais
highqual
antibodi
immun
respons
avian
influenza
human
safeti
immunogen
n
benthamiana
plant
cellderiv
influenza
ha
vlp
vaccin
assess
phase
human
clinic
trial
licens
influenza
vaccin
immunogen
properti
vaccin
exhibit
remark
serolog
respons
measur
hai
titer
singl
radial
hemolysi
srh
microneutr
titer
random
doubleblind
placebocontrol
phase
clinic
trial
perform
among
year
old
healthi
adult
mcgill
univers
health
center
assess
efficaci
plant
cell
deriv
alumadjuv
vlp
intramuscular
immun
vaccin
dose
immunogen
vaccin
ha
vlp
dose
depend
vaccin
subject
high
dose
show
detect
microneutr
titer
clinic
trial
report
high
dose
ha
group
get
first
dose
ha
group
receiv
second
dose
vaccin
subject
experienc
transient
headach
howev
advers
event
mildtomoder
selflimit
anoth
phase
clinic
trial
complet
plant
cell
deriv
ha
season
influenza
vlp
vaccin
evalu
immunogen
safeti
efficaci
clinic
studi
year
old
subject
intramuscularli
administ
havlp
clinic
result
found
safe
well
toler
dose
level
even
dose
vlp
induc
greater
hai
titer
subject
lowvaccin
dose
group
tabl
two
random
phase
ii
clinic
trial
year
old
adult
shown
dose
quadrival
plantderiv
influenza
vlp
vaccin
produc
consist
humor
cellular
respons
recent
phase
iii
clinic
trial
ongo
evalu
efficaci
safeti
immunogen
plantmad
influenza
quadrival
vlp
vaccin
influenza
season
elderli
adult
year
age
older
clinicaltrialsgov
identifi
phase
iii
trial
quadrival
vlp
influenza
vaccin
hastrain
compar
standard
season
vaccin
hastrain
phase
doubleblind
random
clinic
trial
conduct
healthi
volunt
bacteriophag
vlp
vaccin
without
alhydrogel
adjuv
determin
efficaci
immunogen
bacteriophagederiv
influenza
vlp
vaccin
healthi
subject
intramuscularli
immun
vlp
vaccin
contain
ha
antigen
show
similar
antibodymedi
immunogen
compar
safeti
profil
commerci
avail
vaccin
clinic
studi
support
plant
cellderiv
influenza
vlp
vaccin
would
safe
immunogen
clinic
studi
quadrival
vlp
vaccin
safeti
doseescal
studi
comparison
convent
eggderiv
influenza
vaccin
plan
rsv
f
protein
nanoparticl
vaccin
produc
insect
cell
via
rbv
express
system
phase
iii
clinic
trial
studi
rsv
recombin
fusion
f
nanoparticl
vaccin
healthi
women
childbear
age
demonstr
vaccin
safe
immunogen
appear
effect
reduc
rsv
infect
clinic
trial
registr
rsv
f
protein
nanoparticl
vaccin
older
adult
induc
function
immun
rsv
clinicaltrialsgov
number
phase
iii
studi
elderli
year
insect
cellderiv
recombin
rsv
f
nanoparticl
vaccin
fail
demonstr
signific
efficaci
protect
rsv
moder
sever
lower
respiratori
diseas
older
adult
partial
due
lowattack
rate
clinic
trial
yet
evalu
efficaci
rsv
hmpv
vaccin
base
vlp
platform
suggest
technolog
challeng
manufactur
clinicalgrad
rsv
hmpv
vlp
vaccin
stabil
prefus
f
conform
scaleup
process
vlp
vaccin
product
vlp
provid
altern
platform
gener
effect
vaccin
probabl
due
multifari
desir
properti
vlp
selfassembl
express
one
multi
protein
dens
epitop
chimer
protein
present
vlp
surfac
vlp
vaccin
produc
cell
cultur
differ
express
system
compat
formul
variou
adjuv
system
influenza
vlp
vaccin
present
individu
ha
na
combin
vlp
surfac
nativelik
function
glycoprotein
ha
na
protein
vlp
elicit
ha
na
specif
antibodi
howev
due
immunedomin
properti
ha
protein
could
induc
haspecif
antibodi
respons
na
avoid
immunodomin
effect
ha
separ
individu
na
vlp
multival
na
vlp
vaccin
could
altern
approach
influenza
vlp
vaccin
product
scalabl
insect
plant
cellbas
express
system
compar
convent
influenza
split
vaccin
attenu
vaccin
produc
embryon
egg
substrat
influenza
vlp
vaccin
would
stabl
antigen
properti
due
lack
growth
adapt
addit
advantag
manufactur
influenza
vlp
vaccin
requir
handl
live
virus
growth
adapt
case
pandem
outbreak
possibl
produc
distribut
insect
cellderiv
pandem
vlp
vaccin
within
short
time
period
egggrowth
vaccin
egg
cellbas
live
attenu
influenza
vaccin
inactiv
split
influenza
vaccin
would
limit
manufactur
capac
produc
suffici
vaccin
dose
meet
surg
high
vaccin
demand
pandem
outbreak
contrast
plant
cell
express
vlp
rbvinsect
cellbas
express
system
flexibl
coexpress
variou
influenza
viral
structur
protein
surfac
vlp
preclin
well
clinic
studi
report
immun
insect
cellderiv
vlp
induc
effect
serum
neutral
antibodi
high
hai
titer
na
inhibit
antibodi
although
ha
immun
play
major
role
provid
homolog
protect
na
immun
would
contribut
provid
heterolog
cross
protect
clinic
trial
influenza
vlp
vaccin
produc
plant
cell
insect
cell
seriou
advers
event
report
far
combin
vlp
technolog
innov
approach
plant
insect
cell
express
system
lead
develop
effect
influenza
vlp
vaccin
near
futur
product
recombin
purifi
protein
subunit
vaccin
would
cost
high
price
due
multipl
purif
step
provid
high
safeti
featur
overcom
low
immunogen
solubl
protein
technolog
formul
protein
nanoparticl
vaccin
would
highli
desir
nanoparticl
prepar
recombin
protein
influenza
viru
ha
conserv
stalk
domain
tandem
repeat
protein
express
insect
cell
purifi
high
puriti
immunogen
effect
induc
crossprotect
immun
mice
combin
technolog
vlp
vaccin
protein
nanoparticl
vaccin
technolog
would
provid
promis
vaccin
strategi
util
desir
properti
nonrepl
high
immunogen
vlpbase
vaccin
technolog
worthwhil
develop
toward
effect
safe
vaccin
viral
pathogen
difficult
control
crossprotect
influenza
conserv
antigen
conserv
stalk
na
poorli
immunogen
thu
develop
effect
vlp
vaccin
present
cross
protect
antigen
futur
direct
vlp
vaccin
contain
conserv
crossprotect
epitop
induc
nonneutr
immun
would
induc
high
protect
immun
strategi
supplement
habas
vaccin
vlp
contain
conserv
epitop
might
provid
new
vaccin
enhanc
crossprotect
efficaci
current
influenza
vaccin
encourag
outcom
preclin
mous
studi
clinic
trial
influenza
vlp
vaccin
platform
develop
vlp
vaccin
present
influenzaconserv
antigen
immunogen
form
would
provid
new
approach
develop
crossprotect
univers
influenza
vaccin
season
pandem
virus
rsv
vlp
vaccin
demonstr
uniqu
confer
protect
rsv
prevent
vaccineenhanc
respiratori
diseas
upon
rsv
infect
preclin
outcom
rsv
vlp
vaccin
mice
cotton
rat
anim
studi
provid
evid
warranti
develop
effect
safe
rsv
vaccin
would
futur
direct
develop
rsv
vlp
platform
stabli
present
prefus
f
protein
compar
current
pref
version
rsv
prefus
stabil
mutat
foldon
stabil
retain
pref
site
epitop
site
ii
neutral
epitop
solubl
protein
like
addit
mutat
togeth
altern
mutat
rsv
f
requir
stabil
prefus
f
protein
antigen
vlp
platform
rsv
f
nanoparticl
formul
recombin
f
protein
produc
insect
cell
express
system
advanc
clinic
trial
matern
vaccin
protect
infant
although
vaccin
phase
iii
clinic
trial
elderli
success
altern
vaccin
strategi
heterolog
prime
rsv
prefus
f
vlp
boost
pref
protein
nanoparticl
might
futur
studi
develop
effect
safe
rsv
vaccin
hmpv
vlp
vaccin
report
provid
protect
subgroup
b
mous
model
prevent
vaccineenhanc
diseas
hmpv
vlp
remain
test
relev
anim
model
consider
vlp
vaccin
technolog
host
cell
vectorderiv
compon
randomli
pack
togeth
assembl
vlp
sometim
abort
packag
happen
would
impact
gener
immun
respons
vaccin
antigen
probabl
protect
immun
respons
would
depend
manufactur
process
result
differ
batch
vlp
vaccin
also
expect
host
immun
respons
nonvaccin
compon
vlp
vaccin
would
induc
vlp
vaccin
although
immun
respons
nonvaccin
antigen
vector
compon
would
advers
effect
sinc
envelop
virus
influenza
rsv
hmpv
would
contain
host
cellderiv
nonvir
compon
sinc
vlp
platform
vaccin
effect
prime
immun
respons
host
strategi
heterolog
vlp
prime
protein
boost
vaccin
would
enhanc
immun
respons
vaccin
antigen
minim
immun
respons
nonvaccin
vector
compon
advanc
vlp
vaccin
technolog
continu
maxim
protect
vaccin
antigen
content
immunogen
conform
futur
research
effort
